Psilocybin (Arbormentis/Relmada Therapeutics)

赛洛西宾 (Arbormentis/Relmada Therapeutics)

Report date: 2024/02/06 17:54:46

Base Information

Drug NamePsilocybin (Arbormentis/Relmada Therapeutics)
Drug Alias Namemodified-release psilocybin formulation (Arbormentis/Relmada Therapeutics)改释迷幻药制剂REL-P11
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsSerotonin 2a (5-HT2a) receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsNeurodegenerative Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesArbormentis LLCInstitute For Research In BiomedicineUniversity Of Padua
China Registration ClassN/A

Develop Information

Active CompaniesRelmada Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeurodegenerative Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG